Details
Stereochemistry | RACEMIC |
Molecular Formula | C22H23FN4 |
Molecular Weight | 362.4432 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1N(CCC2=C1C=CC=C2)C3=NC(NC4=CC=C(F)C=C4)=NC(C)=C3C
InChI
InChIKey=LECZXZOBEZITCL-UHFFFAOYSA-N
InChI=1S/C22H23FN4/c1-14-15(2)24-22(25-19-10-8-18(23)9-11-19)26-21(14)27-13-12-17-6-4-5-7-20(17)16(27)3/h4-11,16H,12-13H2,1-3H3,(H,24,25,26)
Revaprazan (trade name Revanex) is a drug that reduces gastric acid secretion and is used for the treatment of gastritis and acid-related disease. It acts as an acid pump antagonist (potassium-competitive acid blocker) that reversibly inhibits H+, K+-ATPase by binding to the K+-binding site of the pump, thereby causing fewer side effects, compared with the irreversible proton pump inhibitors. Revaprazan is approved for use in Korea, but is not approved in Europe or the United States.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P05023|||Q9UJ20 Gene ID: 476.0 Gene Symbol: ATP1A1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/18981288 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Revanex Approved Usetreatment of gastritis Launch Date1.15162559E12 |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
The transport of a reversible proton pump antagonist, 5, 6-dimethyl-2-(4-Fluorophenylamino)-4-(1-methyl-1,2,3, 4-tetrahydroisoquinoline-2-yl) pyrimidine hydrochloride (YH1885), across caco-2 cell monolayers. | 2001 Jan |
|
Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers. | 2004 Jan |
|
N-(2-hydroxyethyl)-N,2-dimethyl-8-{[(4R)-5-methyl-3,4-dihydro-2H-chromen-4-yl]amino}imidazo[1,2-a]pyridine-6-carboxamide (PF-03716556), a novel, potent, and selective acid pump antagonist for the treatment of gastroesophageal reflux disease. | 2009 Feb |
|
Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects. | 2010 Oct |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01750437
33.3 - 100 mg YH1885L (Revaprazan) for 4 weeks in patients with non-erosive reflux disease(NERD)
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11124230
Human colon carcinoma cell line, Caco-2. The cells were grown to confluency on a permeable polycarbonate membrane insert to permit loading of YH1885 (revaprazan) on either the apical or basolateral side of the cell monolayer. The flux across the monolayer from the apical to basolateral side was 3 to 5 times greater than that from the basolateral to apical side. The uptake of YH1885 into the Caco-2 cell monolayer was saturable and appeared to be mediated by a high-affinity transporter, with an apparent Km of 1.47+/-0.21 uM and a Vmax of 25.14+/-1.16 pmol/cm(2)/40 s.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29701
Created by
admin on Fri Dec 15 16:14:35 UTC 2023 , Edited by admin on Fri Dec 15 16:14:35 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3525
Created by
admin on Fri Dec 15 16:14:35 UTC 2023 , Edited by admin on Fri Dec 15 16:14:35 UTC 2023
|
PRIMARY | |||
|
DTXSID10870216
Created by
admin on Fri Dec 15 16:14:35 UTC 2023 , Edited by admin on Fri Dec 15 16:14:35 UTC 2023
|
PRIMARY | |||
|
5P184180P5
Created by
admin on Fri Dec 15 16:14:35 UTC 2023 , Edited by admin on Fri Dec 15 16:14:35 UTC 2023
|
PRIMARY | |||
|
m9561
Created by
admin on Fri Dec 15 16:14:35 UTC 2023 , Edited by admin on Fri Dec 15 16:14:35 UTC 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL1618279
Created by
admin on Fri Dec 15 16:14:35 UTC 2023 , Edited by admin on Fri Dec 15 16:14:35 UTC 2023
|
PRIMARY | |||
|
204104
Created by
admin on Fri Dec 15 16:14:35 UTC 2023 , Edited by admin on Fri Dec 15 16:14:35 UTC 2023
|
PRIMARY | |||
|
C76489
Created by
admin on Fri Dec 15 16:14:35 UTC 2023 , Edited by admin on Fri Dec 15 16:14:35 UTC 2023
|
PRIMARY | |||
|
SUB32092
Created by
admin on Fri Dec 15 16:14:35 UTC 2023 , Edited by admin on Fri Dec 15 16:14:35 UTC 2023
|
PRIMARY | |||
|
8415
Created by
admin on Fri Dec 15 16:14:35 UTC 2023 , Edited by admin on Fri Dec 15 16:14:35 UTC 2023
|
PRIMARY | |||
|
199463-33-7
Created by
admin on Fri Dec 15 16:14:35 UTC 2023 , Edited by admin on Fri Dec 15 16:14:35 UTC 2023
|
PRIMARY | |||
|
Revaprazan
Created by
admin on Fri Dec 15 16:14:35 UTC 2023 , Edited by admin on Fri Dec 15 16:14:35 UTC 2023
|
PRIMARY | |||
|
100000124423
Created by
admin on Fri Dec 15 16:14:35 UTC 2023 , Edited by admin on Fri Dec 15 16:14:35 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)